Terms ending in 2041
Every in-force patent on Adimab, LLC's record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,679,892 | B7-H4 Antibodies and Methods of Use Thereof In force · Medium confidence | Five Prime Therapeutics and Adimab, LLC | In force | Medium confidence | |
| US 12,173,059 | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF In force · Medium confidence | Scholar Rock, Inc. | In force | Medium confidence | |
| US 11,192,940 | Compounds Specific to Coronavirus S Protein and Uses Thereof In force · High confidence | Invivyd, Inc. | In force | High confidence | |
| US 11,655,303 | Anti-CD39 Antibody Compositions and Methods In force · Medium confidence | Surface Oncology, Inc. | In force | Medium confidence | |
| US 12,630,624 | ANTI-IL-27 Antibodies and Uses Thereof In force · Low confidence | Surface Oncology, LLC | In force | Low confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Adimab, LLC.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.